Yahoo Finance8d
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...
Nasdaq1mon
Biodexa Pharmaceuticals Receives FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Treatment
Biodexa Pharmaceuticals has announced that the US FDA has granted Fast Track designation for its drug eRapa, an encapsulated ... R&D facility is in Cardiff, UK. For more information visit Certain ...
Yahoo Finance18d
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
Stephen Stamp, CEO and CFO of Biodexa, commented “The FDA has already granted orphan drug designation for our most advanced program, eRapa in FAP which confers seven years market exclusivity from ...
Yahoo Finance8d
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
The U.S. component of the study will be conducted by LumaBridge, based in San Antonio, Texas. The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial ...